Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More

by Zacks Equity Research

Pipeline and regulatory updates from (MRNA) and Amgen (AMGN) are in focus in the biotech sector.

Horizon Therapeutics (HZNP) Up 10.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amgen (AMGN) Stock Outperforms Industry YTD: Here's Why

by Zacks Equity Research

Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset by lower revenues from oncology biosimilars and Enbrel.

FTC Allows Amgen (AMGN) to Proceed With $28B Horizon Buyout

by Zacks Equity Research

Per the settlement terms, Amgen (AMGN) is prohibited from bundling its products with Horizon's Tepezza or Krystexxa. Amgen expects to complete the Horizon acquisition before 2023-end.

Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit

by Zacks Equity Research

The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.

Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales

by Zacks Equity Research

Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.

Company News for Aug 9, 2023

by Zacks Equity Research

Companies in The News Are:LLY,UAA,ATKR,HZNP

Compared to Estimates, Horizon Therapeutics (HZNP) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Horizon Therapeutics (HZNP) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 7.14% and 3.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised

by Zacks Equity Research

Amgen (AMGN) beats Q2 estimates for earnings and sales. It slightly raises its earnings and sales guidance for 2023.

Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 56.52% and 200.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study

by Zacks Equity Research

Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus.

Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal

by Zacks Equity Research

Horizon (HZNP) announces positive top-line results from its phase III study evaluating Tepezza for treating Thyroid Eye Disease with high disease activity in Japan.

Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?

by Zacks Equity Research

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FTC Challenges Amgen's (AMGN) $28B Acquisition of Horizon

by Zacks Equity Research

Per the FTC, Amgen's (AMGN) acquisition of Horizon (HZNP) would entrench the monopoly positions for the latter's medications for thyroid eye disease and chronic refractory gout.

Pfizer (PFE) to Raise $31B in Debt to Fund Seagen (SGEN) Deal

by Zacks Equity Research

Pfizer (PFE) offers bonds worth $31 billion to fund its pending acquisition of cancer drugmaker, Seagen (SGEN).

FTC May Reportedly Block Amgen's (AMGN) $28B Horizon Buyout

by Zacks Equity Research

Unconfirmed reports suggest that the FTC may challenge the $28-billion buyout of Horizon Therapeutics (HZNP) by Amgen.

Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.

Compared to Estimates, Horizon Therapeutics (HZNP) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Horizon Therapeutics (HZNP) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Horizon Therapeutics (HZNP) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -29.06% and 7.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised

by Zacks Equity Research

Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023.

Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EUSA

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

New Strong Buy Stocks for April 14th

by Zacks Equity Research

ABNB, SIGA, DRQ, SWRAY and HZNP have been added to the Zacks Rank #1 (Strong Buy) List on April 14, 2023.